VNDA News
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase DisorderPR NewswireWASHINGTON, Sept. 29, 2026Study met its primary...
PR Newswire
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase DisorderPR NewswireWASHINGTON, Sept. 29, 2026Study met its primary...
PR Newswire
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences PR Newswire WASHINGTON, Sept. 2, 2026 WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA...
PR Newswire
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission PR Newswire...
PR Newswire
NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. PR Newswire WASHINGTON, Aug. 22, 2026 WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc...
PR Newswire
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Zacks
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results PR Newswire WASHINGTON, Aug. 5, 2026 Fanapt Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%Full-year 2026 total revenue...
PR Newswire
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 PR Newswire WASHINGTON, July 29, 2026 Conference Call and Webcast to FollowWASHINGTON, July 29, 2026 /PRNewswire...
PR Newswire
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab...
PR Newswire
NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire WASHINGTON, July 15, 2026 WASHINGTON, July...
PR Newswire